Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Corporate Authors:
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford : Wiley-Blackwell
    • Subject Terms:
    • Abstract:
      Background The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a measure of heart failure (HF) health status. Worse KCCQ scores are common in patients with chronic kidney disease (CKD), even without diagnosed heart failure (HF). Elevations in the cardiac biomarkers GDF-15 (growth differentiation factor-15), galectin-3, sST2 (soluble suppression of tumorigenesis-2), hsTnT (high-sensitivity troponin T), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) likely reflect subclinical HF in CKD. Whether cardiac biomarkers are associated with low KCCQ scores is not known. Methods and Results We studied participants with CKD without HF in the multicenter prospective CRIC (Chronic Renal Insufficiency Cohort) Study. Outcomes included (1) low KCCQ score <75 at year 1 and (2) incident decline in KCCQ score to <75. We used multivariable logistic regression and Cox regression models to evaluate the associations between baseline cardiac biomarkers and cross-sectional and longitudinal KCCQ scores. Among 2873 participants, GDF-15 (adjusted odds ratio 1.42 per SD; 99% CI, 1.19-1.68) and galectin-3 (1.28; 1.12-1.48) were significantly associated with KCCQ scores <75, whereas sST2, hsTnT, and NT-proBNP were not significantly associated with KCCQ scores <75 after multivariable adjustment. Of the 2132 participants with KCCQ ≥75 at year 1, GDF-15 (adjusted hazard ratio, 1.36 per SD; 99% CI, 1.12-1.65), hsTnT (1.20; 1.01-1.44), and NT-proBNP (1.30; 1.08-1.56) were associated with incident decline in KCCQ to <75 after multivariable adjustment, whereas galectin-3 and sST2 did not have significant associations with KCCQ decline. Conclusions Among participants with CKD without clinical HF , GDF-15, galectin-3, NT-proBNP, and hsTnT were associated with low KCCQ either at baseline or during follow-up. Our findings show that elevations in cardiac biomarkers reflect early symptomatic changes in HF health status in CKD patients.
    • References:
      JAMA Cardiol. 2017 Dec 1;2(12):1315-1321. (PMID: 29094152)
      Transplantation. 2008 Sep 27;86(6):804-10. (PMID: 18813105)
      J Am Heart Assoc. 2019 Aug 6;8(15):e012200. (PMID: 31379242)
      Circ Res. 2006 Feb 17;98(3):342-50. (PMID: 16397142)
      J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63. (PMID: 16376782)
      N Engl J Med. 2009 Dec 24;361(26):2538-47. (PMID: 19940289)
      Clin Chim Acta. 2009 Nov;409(1-2):96-9. (PMID: 19747906)
      Circ Heart Fail. 2015 Jul;8(4):702-8. (PMID: 25985796)
      Eur J Heart Fail. 2010 Dec;12(12):1309-16. (PMID: 20837635)
      J Am Coll Cardiol. 2006 Feb 21;47(4):752-6. (PMID: 16487840)
      Am J Kidney Dis. 2012 Aug;60(2):250-61. (PMID: 22658574)
      Am Heart J. 2005 Oct;150(4):707-15. (PMID: 16209970)
      J Card Fail. 2005 Aug;11(6):414-21. (PMID: 16105631)
      J Card Fail. 2005 Jun;11(5 Suppl):S81-3. (PMID: 15948107)
      PLoS One. 2018 May 17;13(5):e0197497. (PMID: 29771963)
      Eur J Heart Fail. 2018 Jan;20(1):55-62. (PMID: 28967680)
      Lancet. 2010 Jun 12;375(9731):2073-81. (PMID: 20483451)
      Am J Kidney Dis. 2018 Oct;72(4):519-528. (PMID: 29866459)
      Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11. (PMID: 19541818)
      Am Heart J. 2012 Jan;163(1):88-94.e3. (PMID: 22172441)
      Eur J Heart Fail. 2009 Feb;11(2):163-9. (PMID: 19168514)
      Brain Res. 2009 Sep 8;1288:116-24. (PMID: 19573520)
      J Am Heart Assoc. 2019 Nov 5;8(21):e012336. (PMID: 31645163)
      Eur J Heart Fail. 2015 Feb;17(2):214-23. (PMID: 25418979)
      J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53. (PMID: 12819321)
      Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1770-7. (PMID: 24876355)
      Heart Fail Rev. 2014 May;19(3):359-67. (PMID: 23681849)
      Clin Chem. 2017 Jan;63(1):140-151. (PMID: 28062617)
      J Am Heart Assoc. 2018 Jul 13;7(14):. (PMID: 30006491)
      JACC Heart Fail. 2015 Mar;3(3):245-52. (PMID: 25742762)
      Circ Heart Fail. 2017 Jan;10(1):. (PMID: 28062537)
      Clin Chim Acta. 2015 May 20;445:155-60. (PMID: 25850080)
      J Card Fail. 2011 Jan;17(1):17-23. (PMID: 21187260)
      Circulation. 2004 Nov 9;110(19):3121-8. (PMID: 15520318)
      Health Qual Life Outcomes. 2010 Sep 13;8:98. (PMID: 20831837)
      Adv Clin Chem. 2015;69:139-59. (PMID: 25934361)
      Clin Chem. 2013 Mar;59(3):536-46. (PMID: 23220272)
      Circ Heart Fail. 2016 Mar;9(3):e001937. (PMID: 26962133)
      J Am Soc Nephrol. 2015 Apr;26(4):946-56. (PMID: 25278510)
      Eur J Prev Cardiol. 2017 Jul;24(11):1127-1135. (PMID: 28452560)
      Am Heart J. 2015 Mar;169(3):404-411.e3. (PMID: 25728731)
      JAMA Cardiol. 2018 Jun 1;3(6):498-505. (PMID: 29617523)
      ESC Heart Fail. 2019 Feb;6(1):3-9. (PMID: 30311454)
      Clin J Am Soc Nephrol. 2013 Mar;8(3):355-62. (PMID: 23411431)
      Circ Res. 2006 Feb 17;98(3):351-60. (PMID: 16397141)
      Eur Respir J. 2017 Mar 15;49(3):. (PMID: 28298399)
      Am J Nephrol. 2010;31(5):426-34. (PMID: 20389058)
      Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004668. (PMID: 29627798)
      JAMA. 2009 Apr 8;301(14):1451-9. (PMID: 19351942)
      J Am Heart Assoc. 2020 Jul 7;9(13):e014385. (PMID: 32578483)
      Curr Heart Fail Rep. 2010 Mar;7(1):9-14. (PMID: 20425491)
    • Grant Information:
      UL1 TR000439 United States TR NCATS NIH HHS; UL1 TR000424 United States TR NCATS NIH HHS; UL1 TR002548 United States TR NCATS NIH HHS; P20 GM109036 United States GM NIGMS NIH HHS; U01 DK061021 United States DK NIDDK NIH HHS; U01 DK060980 United States DK NIDDK NIH HHS; U01 DK060963 United States DK NIDDK NIH HHS; U01 DK060984 United States DK NIDDK NIH HHS; M01 RR013987 United States RR NCRR NIH HHS; R01 DK103612 United States DK NIDDK NIH HHS; UL1 TR000003 United States TR NCATS NIH HHS; M01 RR016500 United States RR NCRR NIH HHS; U01 DK060990 United States DK NIDDK NIH HHS; UL1 RR024131 United States RR NCRR NIH HHS; U01 DK061028 United States DK NIDDK NIH HHS; U01 DK060902 United States DK NIDDK NIH HHS; K24 DK092290 United States DK NIDDK NIH HHS; R01 DK072231 United States DK NIDDK NIH HHS; U01 DK061022 United States DK NIDDK NIH HHS; UL1 TR000433 United States TR NCATS NIH HHS; UL1 RR029879 United States RR NCRR NIH HHS
    • Contributed Indexing:
      Investigator: LJ Appel; HI Feldman; AS Go; PS Rao; M Rahman; RR Townsend
      Keywords: cardiac biomarkers; heart failure; quality of life
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Proteins)
      0 (GDF15 protein, human)
      0 (Galectins)
      0 (Growth Differentiation Factor 15)
      0 (LGALS3 protein, human)
      0 (Peptide Fragments)
      0 (Troponin T)
      0 (pro-brain natriuretic peptide (1-76))
      114471-18-0 (Natriuretic Peptide, Brain)
    • Publication Date:
      Date Created: 20200625 Date Completed: 20210309 Latest Revision: 20211203
    • Publication Date:
      20240628
    • Accession Number:
      PMC7670503
    • Accession Number:
      10.1161/JAHA.119.014385
    • Accession Number:
      32578483